Back to top
more

Boston Scientific (BSX)

(Real Time Quote from BATS)

$86.57 USD

86.57
4,588,579

-1.02 (-1.17%)

Updated Nov 15, 2024 03:04 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (82 out of 250)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

GE Healthcare's (GEHC) Revolution RT to Aid Cancer Treatment

by Zacks Equity Research

GE Healthcare (GEHC) unveils Revolution RT, along with other upgrades, from its portfolio during the ESTRO 2024 Congress.

DENTSPLY SIRONA (XRAY) Q1 Earnings In Line, Revenues Decline Y/Y

by Zacks Equity Research

DENTSPLY SIRONA's (XRAY) first-quarter 2024 results showcase a decline in year-over-year sales with an improved bottom line.

Zimmer Biomet (ZBH) Q1 Earnings Beat, Margins Expand

by Zacks Equity Research

Each of Zimmer Biomet's (ZBH) geographic segments records strong year-over-year sales growth on a reported basis, as well as at CER.

Envista (NVST) Q1 Earnings Miss Estimates, Margins Down

by Zacks Equity Research

Envista (NVST) registers a year-over-year decline in both segments in the first quarter of 2024.

Reasons to Retain Quest Diagnostics (DGX) Stock for Now

by Zacks Equity Research

Investors are optimistic about Quest Diagnostics (DGX) on strong legacy business growth.

Cardinal Health (CAH) Beats on Q3 Earnings, Ups '24 EPS View

by Zacks Equity Research

Cardinal Health's (CAH) third-quarter fiscal 2024 results benefit from solid profit growth in Pharmaceutical and Specialty Solutions. The company raises its EPS guidance for fiscal 2024.

Baxter (BAX) Q1 Earnings Beat Estimates, '24 EPS View Raised

by Zacks Equity Research

Baxter (BAX) reports better-than-expected first-quarter earnings and sales. BAX's quarterly results reflect solid demand for a range of its medically essential products.

BD (BDX) Q2 Earnings Surpass Estimates, FY24 View Revised

by Zacks Equity Research

BD's (BDX) overall top line benefits from revenue growth in all segments and both geographic regions in the fiscal second quarter.

Accuray (ARAY) Q3 Earnings Lag Estimates, Gross Margin Contracts

by Zacks Equity Research

Despite strength in radiation oncology, Accuray (ARAY) reports dismal third-quarter fiscal 2024 results.

Glaukos (GKOS) Q1 Earnings Miss Estimates, Revenues Up Y/Y

by Zacks Equity Research

Glaukos' (GKOS) first-quarter 2024 results showcase growth in revenues while earnings miss the Zacks consensus Estimate. Loss at the operating level raises concern as well.

Here's Why You Should Retain STERIS (STE) Stock for Now

by Zacks Equity Research

STERIS' (STE) strong prospects in the healthcare and pharmaceutical industries bode well for investors.

Merit Medical (MMSI) Q1 Earnings Top Estimates, Margins Up

by Zacks Equity Research

Merit Medical (MMSI) benefits from revenue growth in both segments and the majority of its product categories within its Cardiovascular unit in the first quarter.

CVS Health's (CVS) Q1 Earnings Miss Estimates, Margins Up

by Zacks Equity Research

CVS Health's (CVS) Q1 performance is impacted by a decline in the Health Services segment due to continued pharmacy client price improvements.

Inari Medical (NARI) Q1 Earnings Miss Estimates, OpEx Rises

by Zacks Equity Research

Inari Medical's (NARI) first-quarter results witness an increase in revenues with dismal bottom-line performance. Gross margins contract while the companies continue to incur operating losses.

IDEXX (IDXX) Q1 Earnings Surpass Estimates, 2024 View Slashed

by Zacks Equity Research

IDEXX (IDXX) delivers better-than-expected earnings in the first quarter of 2024.

Stryker's (SYK) Q1 Earnings Beat Estimates, Guidance Raised

by Zacks Equity Research

Stryker's (SYK) first-quarter earnings reflect strong performance across its segments and geographies. Operating and gross margins increase, with earnings and revenues beating their respective estimates.

Cencora (COR) Q2 Earnings Top Estimates, 2024 View Raised

by Zacks Equity Research

Cencora's (COR) second-quarter fiscal 2024 results benefit from overall market growth, including rising demand for GLP-1 drugs and COVID-19 vaccines. Inflationary pressure remains.

Ecolab (ECL) Q1 Earnings Surpass Estimates, Margins Rise

by Zacks Equity Research

Ecolab's (ECL) robust performance across the majority of its segments drives its first-quarter sales despite business challenges.

QIAGEN (QGEN) Q1 Earnings Top Estimates, Margins Expand

by Zacks Equity Research

QIAGEN (QGEN) Q1 results are driven by solid growth in consumables and ongoing higher instruments placements.

Avantor (AVTR) Q1 Earnings Surpass Estimates, Margins Down

by Zacks Equity Research

Despite Avantor's (AVTR) continued stability in end markets, it reports an overall soft first-quarter performance.

Is Boston Scientific (BSX) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Boston Scientific (BSX) and Canopy Growth Corporation (CGC) have performed compared to their sector so far this year.

The Zacks Analyst Blog Highlights 10x Genomics, Cardinal Health, Hologic, Boston Scientific and LabCorp

by Zacks Equity Research

10x Genomics, Cardinal Health, Hologic, Boston Scientific and LabCorp are included in this Analyst Blog.

Urmimala Biswas headshot

3 Medical Products Stocks Set to Beat This Earnings Season

by Urmimala Biswas

Here are three stocks, TXG, CAH and HOLX, which are expected to beat earnings estimates in the ongoing reporting cycle.

Here's Why Boston Scientific (BSX) is a Strong Momentum Stock

by Zacks Equity Research

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Why Boston Scientific (BSX) is a Top Growth Stock for the Long-Term

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.